Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 1 of 2 (50%) have an AI response strategy ready • 4 patents granted in the last 365 days
Gruenenthal GmbH currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by distinct examiners, but they are both located within 1 distinct art unit. YOO, SUN JAE is identified as the busiest examiner for the company, currently overseeing 1 pending office action.
The concentration of 2 pending office actions within the art unit suggests a consistent technical focus for the company's filings. Although there are multiple examiners involved, the 1 distinct art unit means they likely follow similar procedural guidelines. This structure allows the company to benefit from a specialized review process while managing the feedback from different individuals.
Practitioners should note that with the pending action assigned to the busiest examiner, YOO, SUN JAE, the workload is split. The presence of the 2 pending office actions in the Biotechnology & Pharmaceuticals sector requires a coordinated legal strategy. By focusing on the standards of the art unit, the company can ensure that its arguments remain technically consistent across both matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17866672 | QUINOXALINE DERIVATIVES | WARD, PAUL V | 36d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18644851 | Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives | YOO, SUN JAE | — | §103 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 17866672 | QUINOXALINE DERIVATIVES | WARD, PAUL V | 1622 | §102 | Final Rejection | 36d overdue | AI Ready | Jul 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial